4-(1-ethyl-piperidin-4-ylmethyl)-3-trifluoromethyl-phenylamine | 1020662-74-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(1-ethyl-piperidin-4-ylmethyl)-3-trifluoromethyl-phenylamine
• 英文别名: 4-[(1-Ethylpiperidin-4-yl)methyl]-3-(trifluoromethyl)aniline
• CAS: 1020662-74-1
• 化学式: C₁₅H₂₁F₃N₂
• 分子量: 286.34
• InChiKey: BFEBCONAELGUEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(1-ethyl-piperidin-4-ylmethyl)-3-trifluoromethyl-phenylamine 、 2-(4-(pyridin-3-yl)phenoxy)acetic acid 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以25 mg的产率得到N-(4-((1-ethylpiperidin-4-yl)methyl)-3-(trifluoromethyl)phenyl)-2-(4-(pyridin-3-yl)phenoxy)acetamide
  参考文献：
  名称：

  Structure–Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells

  摘要：

  Clinically used BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia do not eliminate leukemic stem cells (LSC). It has been shown that MNK1 and 2 inhibitors prevent phosphorylation of eIF4E and eliminate the self-renewal capacity of LSCs. Herein, we describe the identification of novel dual MNK1 and 2 and BCR-ABL1 inhibitors, starting from the known kinase inhibitor 2. Initial structure activity relationship studies resulted in compound 27 with loss of BCR-ABL1 inhibition. Further modification led to orally bioavailable dual MNK1 and 2 and BCR-ABL1 inhibitors 53 and 54, which are efficacious in a mouse xenograft model and also reduce the level of phosphorylated eukaryotic translation initiation factor 4E in the tumor tissues. Kinase selectivity of these compounds is also presented.

  DOI：

  10.1021/acs.jmedchem.5b01712
• 作为产物：
  描述：

  1-(溴甲基)-4-硝基-2-(三氟甲基)苯 在 platinum on activated charcoal 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 、 mineral oil 为溶剂， 100.0 ℃ 、344.75 kPa 条件下， 反应 37.0h， 生成 4-(1-ethyl-piperidin-4-ylmethyl)-3-trifluoromethyl-phenylamine
  参考文献：
  名称：

  Structure–Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells

  摘要：

  Clinically used BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia do not eliminate leukemic stem cells (LSC). It has been shown that MNK1 and 2 inhibitors prevent phosphorylation of eIF4E and eliminate the self-renewal capacity of LSCs. Herein, we describe the identification of novel dual MNK1 and 2 and BCR-ABL1 inhibitors, starting from the known kinase inhibitor 2. Initial structure activity relationship studies resulted in compound 27 with loss of BCR-ABL1 inhibition. Further modification led to orally bioavailable dual MNK1 and 2 and BCR-ABL1 inhibitors 53 and 54, which are efficacious in a mouse xenograft model and also reduce the level of phosphorylated eukaryotic translation initiation factor 4E in the tumor tissues. Kinase selectivity of these compounds is also presented.

  DOI：

  10.1021/acs.jmedchem.5b01712

文献信息

• Phenylacetamides being FLT3 Inhibitors
  申请人：Furet Pascal

  公开号：US20100075980A1

  公开（公告）日：2010-03-25

  Compounds of formula wherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like. The compounds are protein kinase inhibitors and can be used for the treatment of diseases mediated by protein kinase inhibitors, e.g. for the treatment of various proliferative diseases.

  该专利涉及公式中残基R1、R2、R3、R9、R10和Q以及X、Y和Z的化合物，其盐；它们的使用，使用方法，生产过程，包含它们的制药组合物，它们与第二药物物质的组合及其使用等。这些化合物是蛋白激酶抑制剂，可用于治疗由蛋白激酶抑制剂介导的疾病，例如用于治疗各种增殖性疾病。
• US7977338B2
  申请人：——

  公开号：US7977338B2

  公开（公告）日：2011-07-12